About XORTX Therapeutics
XORTX Therapeutics (CVE:XRTX), (NASDAQ:XRTX) focuses on developing innovative therapies aimed at treating kidney disease and conditions that lead to kidney damage. It is traded on the NASDAQ stock exchange under the ticker symbol XRTX. The company is dedicated to advancing its clinical programs to address unmet medical needs in the treatment of progressive kidney disease. XORTX's projects primarily involve the development of therapeutic solutions that target the underlying causes of kidney damage, including high uric acid levels and oxidative stress. Their objective is to improve the quality of life for patients suffering from these debilitating conditions through the advancement of their research and development efforts. By leveraging its expertise in kidney health, XORTX is committed to bringing novel treatments to market that can offer hope and improved outcomes for patients facing kidney-related health challenges.
Snapshot
Operations
Products and/or services of XORTX Therapeutics
- Development of novel therapeutics to treat progressive kidney disease in autosomal dominant polycystic kidney disease and other chronic kidney diseases.
- Advancement of XRx-008 program for Alport syndrome, aiming to reduce hyperuricemia and improve kidney function.
- Research on XRx-101, a formulation designed to mitigate acute kidney injury resulting from contrast media administration during medical procedures.
- Exploration of treatments targeting uric acid pathways to address rare kidney diseases and potentially extend to more common renal ailments.
- Investigation into metabolic syndrome interventions, focusing on therapeutics to manage and mitigate its impact on kidney health.
- Pursuit of partnerships and collaborations to expand research and development efforts in kidney disease and related metabolic disorders.
XORTX Therapeutics executive team
- Dr. Allen Warren Davidoff Ph.D.Founder, CEO, President & Director
- Dr. Michael Scott Bumby D.V.M., M.B.A.Chief Financial Officer
- Dr. Stephen Haworth M.D., MRCPChief Medical Officer
- Dr. Stacy Evans M.B.A., M.D.Chief Business Officer
- Nick RigopoulosDirector of Communications
- Dr. David Sans M.B.A., Ph.D.Director of Corporate Development
- Dr. David MacDonald Ph.D.Consultant of Clinical Operations
- Ms. Charlotte MayCorporate Secretary